Target150's own research is a software programme, run with KXCO and still in development. It is not in use with patients. Further down we summarise published stem cell research from around the world: that work was carried out and published by other groups, not by Target150.
Technology research
Target150 runs a software research programme with KXCO, built on Round Table, KXCO's proprietary ontology engine. The aim is a set of AI tools for longevity, patient care and patient management, developed to the standard required of software a clinician is going to rely on. The work is in development. Nothing described below is in use at the clinic, and no part of it has been tested on a patient.
Longevity medicine asks software to do more than store data. The moment a tool informs a clinical judgement it is a medical device, and we treat it as one from the first line of code. The programme is scoped against the frameworks that govern regulated health software, including IEC 62304 for the software lifecycle, ISO 13485 for the quality system, and the Thai FDA's guidance on software as a medical device and artificial intelligence.
A consultation lasts a few hours. A longevity programme runs for decades. The remote side of that is under development here: tools that carry a patient's programme forward while they are at home, in another country, or under the care of another doctor, and that hand the clinician a picture worth reading rather than a stream of raw numbers.
Most medical records are a pile of documents from systems that never speak to each other. We are building the patient record instead as one continuous account of what is true, what was true before, and who said so. Round Table is built for exactly that: every claim carries two independent dates, when it was true and when it was asserted, so nothing can be backdated, and a claim that stops being true is marked superseded and dated rather than quietly deleted.
The parts of a clinic visit a patient notices least are the ones that fail most often: intake, consent, orders, results, referrals, scheduling, insurance, billing and follow-up. We are treating that entire sequence as one system rather than a dozen unrelated ones, so a patient's clinical history, their consent and their account always agree with each other.
This is research and development, and the specifics stay in-house while the work is in progress. Nothing described here is in clinical use, none of it has been tested on a patient, none is sold as a product today, and none is a cleared or certified medical device. None of it replaces a consultation with a clinician. Round Table is KXCO's proprietary engine and is not publicly available. A public demonstration of what the engine does is published at kxco.ai/ontology-live.
Published research
The studies below were conducted and published by other research groups. Target150 does not run clinical trials or clinical research of its own and did not carry out this work. Outside the approved indications, the uses described remain investigational.
Research Outcome:
Several studies have shown that stem cell therapy, particularly with induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs), has led to improvements in motor function in patients with spinal cord injuries. A key study published in The Lancet (2017) found that MSC transplantation significantly improved motor skills in patients with spinal cord injuries, enhancing their quality of life.
Conclusion:
Stem cell-based treatments hold promise for spinal cord injury recovery, promoting tissue regeneration and neural repair.
Research Outcome:
Clinical trials exploring the use of stem cells for heart disease, such as the one published in Circulation Research (2019), have shown promising results in regenerating damaged heart tissue following a heart attack. The use of iPSCs and cardiac progenitor cells helped to restore heart function and reduce scarring in animal models, and similar improvements were seen in early human trials.
Conclusion:
Stem cell-based approaches for heart disease show potential in improving heart function and reducing heart failure symptoms.
Research Outcome:
Studies on Parkinson's disease have shown positive results in using stem cells to regenerate dopamine-producing neurons. A landmark study from Nature (2018) found that stem cells derived from iPSCs were able to successfully differentiate into dopaminergic neurons and improve motor function in animal models. Ongoing trials in humans are evaluating the efficacy of these treatments.
Conclusion:
Stem cells could offer a promising treatment for Parkinson's disease by restoring lost dopamine-producing neurons, potentially halting or reversing disease progression.
Research Outcome:
Stem cell therapy has also shown promise in type 1 diabetes (TID) treatment. In a study published in Cell Stem Cell (2020), researchers demonstrated that stem cells could be used to create insulin-producing beta cells, which the authors describe as a potential future treatment route for type 1 diabetes. Early human trials have shown some success in creating functional pancreatic cells that produce insulin.
Conclusion:
Stem cells could provide a pathway to a long-term solution for type 1 diabetes by generating functional insulin-producing cells.
(e.g., Multiple Sclerosis)
Research Outcome:
A clinical study published in JAMA Neurology (2019) explored the use of hematopoietic stem cell transplantation (HSCT) in patients with multiple sclerosis (MS). Results indicated that patients who underwent HSCT experienced remission or reduced disease activity. The therapy works by resetting the immune system, which is responsible for the autoimmune response in MS.
Conclusion:
Stem cell therapies have demonstrated significant efficacy in treating autoimmune diseases like MS by modulating the immune system and promoting tissue repair.
Research Outcome:
Mesenchymal stem cells (MSCs) have shown promise in treating osteoarthritis (OA). A study published in The Lancet (2020) demonstrated that MSC injections into damaged joints could improve cartilage regeneration and reduce pain in OA patients, potentially offering a non-invasive alternative to joint replacement surgery.
Conclusion:
Stem cell therapy is emerging as a potential treatment for osteoarthritis, helping to repair cartilage and alleviate symptoms.
(e.g.. Age-Related Macular Degeneration)
Research Outcome:
Stem cell therapies have shown promise in treating retinal diseases. A clinical trial published in Stem Cell Reports (2021) demonstrated that retinal pigment epithelium (RPE) cells derived from stem cells were successfully transplanted into patients with age-related macular degeneration (AMD), leading to improved vision and stabilization of retinal function.
Conclusion:
Stem cell treatments hold great promise for treating age-related macular degeneration and other retinal diseases, offering hope for restoring vision.
Research Outcome:
Research has shown that stem cells, particularly neural stem cells (NSCs), can aid in recovery from stroke by promoting neurogenesis and tissue repair. A study published in Stem Cells Translational Medicine (2020) found that patients who received NSC transplants showed improvement in motor and cognitive functions, as well as a reduction in the size of the stroke-induced brain lesion.
Conclusion:
Stem cell therapy could play a significant role in stroke recovery by promoting tissue regeneration and improving neurological function.
Research Outcome:
A study published in Cell Transplantation (2019) demonstrated that stem cell therapy could stimulate hair regrowth in individuals with alopecia. Researchers have used dermal papilla cells and iPSCs to generate hair follicles, with positive results showing new hair growth in animal models and early human trials.
Conclusion:
Stem cell therapy offers a potential new treatment for hair loss, providing an alternative to traditional methods like hair transplants.
Research Outcome:
Stem cells, particularly MSCs, have been found to improve bone and muscle regeneration. A study published in Nature Medicine (2019) demonstrated that MSC-based therapies significantly improved healing in bone fractures, and another study showed improvements in muscle regeneration in animal models of muscular dystrophy.
Conclusion:
Stem cell therapy has significant potential for regenerating bone and muscle tissue, offering hope for patients with fractures, osteoporosis, or degenerative muscle diseases.
While much of the research on stem cell therapy is still in its early stages or undergoing clinical trials, the results so far are promising across a range of conditions, from spinal cord injuries to heart disease, neurodegenerative disorders, autoimmune diseases, and beyond. These therapies are a promising direction for regenerative medicine, with the potential to improve quality of life for patients with conditions that currently have limited treatment options. However, continued research and clinical trials are essential to fully understand the long-term benefits and risks.
Common questions
Target150 runs a software research programme with KXCO, aimed at AI tools for longevity, patient care and patient management, covering software as a medical device, remote care, the patient record, and the clinic interaction from care through to billing. It is in development, not in clinical use, has not been tested on patients, is not sold as a product, and is not a cleared or certified medical device. It is the only research programme Target150 runs: the stem cell studies on this page were published by other groups.